Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alkermes plc
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.
- Other Names / Subsidiaries
- Rodin Therapeutics, Inc.